UnitedHealth Gains Analyst Favor Amid Strategic AI Push

Raymond James upgrades UnitedHealth to Outperform, citing a $1.5B AI investment to cut costs and boost Optum margins. Stock target is $330.

Market sentiment toward U.S. healthcare giant UnitedHealth Group is improving, following a period marked by regulatory pressures and rising medical costs. Analysts at Raymond James now believe the peak of investor skepticism has passed, leading to a notable upgrade for the company's shares. Central to this renewed confidence is a multi-billion dollar commitment to artificial intelligence, aimed at restoring margin strength within its Optum services division.

On Wednesday, the research firm elevated its rating on the stock from "Market Perform" to "Outperform," simultaneously establishing a new price target of $330. In their view, the current valuation reflects an excessive degree of caution, underestimating the recovery potential embedded in the company's service-based operations. This assessment arrives as the market has already begun to price the shares more favorably; the stock has advanced over 7% in the past week, recently trading at 240.40 euros.

A $1.5 Billion Bet on Operational Efficiency

The anticipated margin enhancement at subsidiary Optum forms the cornerstone of the bullish outlook. Company leadership is executing a strategic overhaul of its cost structure, backed by a planned investment of $1.5 billion into AI and automated platform technologies.

The initiative is projected to reduce annual operating expenses by $1 billion by the end of 2026. This would lower the operating cost ratio from 13.3% to 12.8%. A key component of this strategy is a new AI assistant named "Avery," designed to automate millions of customer service inquiries with a targeted first-contact resolution rate of 90%.

Regulatory Landscape Presents Ongoing Challenges

Despite these operational advancements, UnitedHealth continues to operate within a complex regulatory framework. Significant risk persists in its Medicare Advantage segment due to ongoing audits of risk adjustment data (RADV audits). Furthermore, a pending ruling from the Ninth Circuit Court could influence future liability scenarios for the insurer.

Accounting for these legal variables, the company's full-year 2026 adjusted earnings forecast remains above $17.75 per share. Factoring in all elements, the current average price target among Wall Street analysts stands at $363.38.